Accredited by The Accrediting Council for Continuing Education & Training

ACCET


BioHealth College is approved by the State of California Department of Consumer Affairs - Bureau of Private Postsecondary Education



Check our
Education Partners section for a complete list of our partners in education.


Campus Location

2665 North First Street, Suite 102
San Jose, CA 95134
Call Us 408.428.0208


Request Campus Tour

Fill out the form below for a campus tour of BioHealth College

Request Information



Talk to us live -
click here to talk with us LIVE or fill out our information request form

BioHealth College Campus

BioHealth College on KNTV NBC Bay Area


BioHealth College on KGO TV ABC


BioHealth College welcomes a visit from Congresswoman Zoe Lofgren

Zoe Lofgren

Recently BioHealth College was honored to have our district’s Congresswoman, Zoe Lofgren visit our campus. We were able to share with her the details of the programs we offer as well as some success stories of some of our graduates.

This was especially exciting since both Education and Innovation in Biotechnology are two areas that are high on the Congresswoman’s priorities and play major rolls in her vision for the future of Silicon Valley.


Life Science Investing Rises 52% from First Quarter, Biotech takes top spot in Q2 VC investment

NASDAQ

The National Venture Capital Association (NVCA) has released second quarter investment numbers, and once again the life sciences sector (biotechnology and medical device industries combined) leads the pack. As in Q1, biotech received the highest level of funding, rising 59 percent in dollars and 34 percent in deal volume in the second quarter with $1.3 billion going into 139 deals. Overall, life sciences investing jumped 52 percent in dollars and 36 percent in deals over Q1 levels. Seed and early stage deals surged in Q2, while biotech, software and industrial/energy industries received the highest level of first-time dollars.

NVCA President Mark Heesen notes that the end of the biotech IPO drought contributed significantly to the rebound in Q2 VC investments. "As the exit market begins to show signs of life, venture capitalists are now able to look increasingly at new investments outside their existing portfolio. This dynamic translates into momentum in the seed and early stage sectors where valuations remain reasonable and opportunities are great."